Sector News

ATyr slashes headcount, cuts costs after ORCA runs aground

May 14, 2018
Life sciences

ATyr Pharma is laying off 30% of its staff and otherwise cutting its costs in response to lackluster data. The biotech made the cuts after preclinical data on its anticancer antibodies suggested they lack the required efficacy.

San Diego, California-based aTyr made ORCA its third program after identifying a link between the resokine pathway—the backbone of its pipeline—and the ways tumors evade the immune system. The link suggested aTyr could deploy its knowledge of the resokine pathway to develop that most desirable of assets: a drug that makes checkpoint inhibitors more effective.

ATyr’s belief in the theory was brief. Researchers presented initial data on the program at the start of the year, emboldening aTyr to predict a 2019 move into the clinic. Subsequent readouts put pay to that plan.

Details of the data have yet to emerge, but aTyr said what it learned over the past month suggests its ORCA antibodies lack the efficacy to advance. That prompted aTyr to call off IND-enabling activities and layoff staff. ATyr’s diminished resources are now focused on its last hope, ATYR1923.

ORCA’s importance to aTyr grew last year when the biotech made it one of the focal points of its R&D. Resolaris, a treatment for rare muscular dystrophies, used to be the top priority at aTyr, but the company dialed down its interest after getting a look at early clinical data. With Resolaris on the backburner, ORCA and ATYR1923 stepped into the limelight.

The two-pronged R&D focus was short lived, though. ATYR1923 is the only one game in town for the newly slimmed-down aTyr.

“Going forward, we are primarily focused on ATYR1923 and designing a future patient trial which will be influenced by data from our ongoing phase I trial, translational activities and research related to the role of the receptor for ATYR1923,” aTyr CEO Sanjay Shukla, M.D., said in a statement.

ATyr had $74.1 million in the bank as of the end of March.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.